PIK-93PI3Kγ/PI4KIIIβ/PI3Kα inhibitor CAS# 593960-11-3 |
2D Structure
- IPI-145 (INK1197)
Catalog No.:BCC1104
CAS No.:1201438-56-3
- IC-87114
Catalog No.:BCC1161
CAS No.:371242-69-2
- PI-103
Catalog No.:BCC1162
CAS No.:371935-74-9
- PIK-75
Catalog No.:BCC1163
CAS No.:372196-77-5
- TGX-221
Catalog No.:BCC1244
CAS No.:663619-89-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 593960-11-3 | SDF | Download SDF |
PubChem ID | 6852167 | Appearance | Powder |
Formula | C14H16ClN3O4S2 | M.Wt | 389.88 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 150 mg/mL (384.73 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-[5-[4-chloro-3-(2-hydroxyethylsulfamoyl)phenyl]-4-methyl-1,3-thiazol-2-yl]acetamide | ||
SMILES | CC1=C(SC(=N1)NC(=O)C)C2=CC(=C(C=C2)Cl)S(=O)(=O)NCCO | ||
Standard InChIKey | JFVNFXCESCXMBC-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C14H16ClN3O4S2/c1-8-13(23-14(17-8)18-9(2)20)10-3-4-11(15)12(7-10)24(21,22)16-5-6-19/h3-4,7,16,19H,5-6H2,1-2H3,(H,17,18,20) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | PIK-93 is the first potent, synthetic inhibitor of PI3Kγ, PI4KIIIβ and PI3Kα with IC50 values of 16 nM, 19 nM and 39nM, respectively. | ||||||
Targets | PI3Kγ | PI4KIIIβ | PI3Kα | DNA-PK | PI3Kδ | ||
IC50 | 16 nM | 19 nM | 39 nM | 64 nM | 120 nM |
PIK-93 Dilution Calculator
PIK-93 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5649 mL | 12.8245 mL | 25.6489 mL | 51.2978 mL | 64.1223 mL |
5 mM | 0.513 mL | 2.5649 mL | 5.1298 mL | 10.2596 mL | 12.8245 mL |
10 mM | 0.2565 mL | 1.2824 mL | 2.5649 mL | 5.1298 mL | 6.4122 mL |
50 mM | 0.0513 mL | 0.2565 mL | 0.513 mL | 1.026 mL | 1.2824 mL |
100 mM | 0.0256 mL | 0.1282 mL | 0.2565 mL | 0.513 mL | 0.6412 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PIK-93 is a potent and novel inhibitor of p110γ (PI3Kγ) and PI4KIIIβ (IC50= 16 nM and 19 nM, respectively).
PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) is a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. It plays a key role in PI3K/Akt/mTOR pathway.
Inhibition of PI3K via PIK-93 reduced the carbachol-activated translocation of TRPC6 to the plasma membrane and carbachol-activated net Ca(2+) entry into T6.11 cells. [1] PIK-93 also selectively inhibited the PI4KIIIβ enzyme, and siRNA-mediated down regulation of individual PI4-enzymes in COS-7 cells. [2] Furthermore, as a potent anti-PV compound, PIK93 targeted PI4Kβ to inhibit interaction of viral 3D polymerase and phosphatidylinositol 4-phosphate on the reorganized membrane vesicle for viral replication complex formation. [3] PIK93 also showed anti-PV with an EC50 of 0.14 μM for PV pseudovirus infection. [4]
References:
[1] Monet M, Francoeur N, Boulay G. Involvement of phosphoinositide 3-kinase and PTEN protein in mechanism of activation of TRPC6 protein in vascular smooth muscle cells. J Biol Chem. 2012 May 18;287(21):17672-81.
[2] Tóth B, Balla A, Ma H et al. Phosphatidylinositol 4-kinase IIIbeta regulates the transport of ceramide between the endoplasmic reticulum and Golgi. J Biol Chem. 2006 Nov 24;281(47):36369-77.
[3] Hsu, N. Y., et al. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811.
[4] Arita M, Kojima H, Nagano T et al. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol. 2011 Mar;85(5):2364-72.
- Alizapride HCl
Catalog No.:BCC4618
CAS No.:59338-87-3
- Triacontanol
Catalog No.:BCC8260
CAS No.:593-50-0
- Lindleyin
Catalog No.:BCN8450
CAS No.:59282-56-3
- Vitexin 2''-O-p-coumarate
Catalog No.:BCN2793
CAS No.:59282-55-2
- Sissotrin
Catalog No.:BCN4095
CAS No.:5928-26-7
- Decursin
Catalog No.:BCN5335
CAS No.:5928-25-6
- Acyclovir
Catalog No.:BCC3929
CAS No.:59277-89-3
- Meptazinol HCl
Catalog No.:BCC4920
CAS No.:59263-76-2
- Rigosertib sodium
Catalog No.:BCC4067
CAS No.:592542-60-4
- Rigosertib
Catalog No.:BCC4296
CAS No.:592542-59-1
- Chikusetsu Saponin Ib
Catalog No.:BCC8308
CAS No.:59252-87-8
- Laurocapram
Catalog No.:BCN8308
CAS No.:59227-89-3
- Darutigenol
Catalog No.:BCN4096
CAS No.:5940-00-1
- Boc-HoSer(Bzl)-OH
Catalog No.:BCC3244
CAS No.:59408-74-1
- 1F-Fructofuranosylnystose
Catalog No.:BCN8287
CAS No.:59432-60-9
- 1-Methyl-2-undecylquinolin-4(1H)-one
Catalog No.:BCN6591
CAS No.:59443-02-6
- Monotropein
Catalog No.:BCN6280
CAS No.:5945-50-6
- Nimbin
Catalog No.:BCN4617
CAS No.:5945-86-8
- Dihydropyrocurzerenone
Catalog No.:BCN8061
CAS No.:59462-26-9
- NSC 146109 hydrochloride
Catalog No.:BCC2410
CAS No.:59474-01-0
- Tafamidis
Catalog No.:BCC5268
CAS No.:594839-88-0
- Z-D-Glu(OBzl)-OH
Catalog No.:BCC2772
CAS No.:59486-73-6
- Citric acid monohydrate
Catalog No.:BCN8492
CAS No.:5949-29-1
- Testosterone undecanoate
Catalog No.:BCC9173
CAS No.:5949-44-0
Involvement of phosphoinositide 3-kinase and PTEN protein in mechanism of activation of TRPC6 protein in vascular smooth muscle cells.[Pubmed:22493444]
J Biol Chem. 2012 May 18;287(21):17672-81.
TRPC6 is a cation channel in the plasma membrane that plays a role in Ca(2+) entry after the stimulation of a G(q)-protein-coupled or tyrosine-kinase receptor. TRPC6 translocates to the plasma membrane upon stimulation and remains there as long as the stimulus is present. However, the mechanism that regulates the trafficking and activation of TRPC6 are unclear. In this study we showed phosphoinositide 3-kinase and its antagonistic phosphatase, PTEN, are involved in the activation of TRPC6. The inhibition of PI3K by PIK-93, LY294002, or wortmannin decreased carbachol-induced translocation of TRPC6 to the plasma membrane and carbachol-induced net Ca(2+) entry into T6.11 cells. Conversely, a reduction of PTEN expression did not affect carbachol-induced externalization of TRPC6 but increased Ca(2+) entry through TRPC6 in T6.11 cells. We also showed that the PI3K/PTEN pathway regulates vasopressin-induced translocation of TRPC6 to the plasma membrane and vasopressin-induced Ca(2+) entry into A7r5 cells, which endogenously express TRPC6. In summary, we provided evidence that the PI3K/PTEN pathway plays an important role in the translocation of TRPC6 to the plasma membrane and may thus have a significant impact on Ca(2+) signaling in cells that endogenously express TRPC6.
Mitigating Motor Neuronal Loss in C. elegans Model of ALS8.[Pubmed:28912432]
Sci Rep. 2017 Sep 14;7(1):11582.
ALS8 is a late-onset familial autosomal dominant form of Amyotrophic Lateral Sclerosis (ALS) caused by a point mutation (P56S) in the VAPB gene (VAMP associated protein isoform B). Here, we generated two C. elegans models of the disease: a transgenic model where human VAPB wild-type (WT) or P56S mutant was expressed in a subset of motor neurons, and a second model that targeted inducible knockdown of the worm's orthologue, vpr-1. Overexpression of human VAPB in DA neurons caused a backward locomotion defect, axonal misguidance, and premature neuronal death. Knockdown of vpr-1 recapitulated the reduction in VAPB expression associated with sporadic cases of human ALS. It also caused backward locomotion defects as well as an uncoordinated phenotype, and age-dependent, progressive motor neuronal death. Furthermore, inhibiting phosphatidylinositol-4 (PtdIns 4)-kinase activity with PIK-93 reduced the incidence of DA motor neuron loss and improved backward locomotion. This supports the loss of VAPB function in ALS8 pathogenesis and suggests that reducing intracellular PtdIns4P might be an effective therapeutic strategy in delaying progressive loss of motor neurons.